Search - tctmd.com

Displaying 1 - 20 of 83

Sort: Relevancy | Date

News Conference News AHA 2016

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

L.A. McKeown

November 17, 2016

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

Presentation TCT 2016

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Presenter: Michael Argenziano, Alec S. Vahanian, Patrick T. O'Gara

October 31, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Daily News

Thrombus Relatively Common After LAA Occlusion With Amplatzer Amulet, Small Study Suggests

Todd Neale

July 28, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

News Features

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Caitlin E. Cox

June 17, 2016

Presentation TVT 2016

Study Design for the EVOLUT R Low-Risk Trial

Presenter: Jeffrey J. Popma

June 16, 2016

News Daily News

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Michael O'Riordan

June 07, 2016

News Daily News

US and European Heart Failure Guidelines Advocate Use of Two New Therapies

L.A. McKeown

May 24, 2016

News Conference News EuroPCR 2016

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Michael O'Riordan

May 23, 2016

News Daily News

Real-World Study Largely Confirms Effects of Apixaban, Rivaroxaban for A-fib

Todd Neale

April 21, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Shelley Wood

April 02, 2016

Advertisement

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Thrombus Relatively Common After LAA Occlusion With Amplatzer Amulet, Small Study Suggests

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

What TAVR Needs Next . . . and What It’s Getting

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Study Design for the EVOLUT R Low-Risk Trial

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

US and European Heart Failure Guidelines Advocate Use of Two New Therapies

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Real-World Study Largely Confirms Effects of Apixaban, Rivaroxaban for A-fib

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content